NLS Pharmaceutics AG (NLSP)
| Previous Close | 0.6200 |
| Open | 0.5750 |
| Bid | 0.5600 x 2200 |
| Ask | 0.6400 x 1000 |
| Day's Range | 0.5675 - 0.6080 |
| 52 Week Range | 0.5500 - 3.7300 |
| Volume | |
| Avg. Volume | 117,409 |
| Market Cap | 8.37M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6910 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- ACCESSWIRE
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
(NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that 90% of the 60 patients required to complete its Phase 2a clinical trial for Quilience (Mazindol ER) have been randomized and the Company continues to expect to report final results from this ground-breaking trial by mid-Q3 2022."Since our initial public o
- ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd.04 per common share (or common share equivalent).
- ACCESSWIRE
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the B.
